Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain

Hum Vaccin Immunother. 2021 Mar 4;17(3):654-655. doi: 10.1080/21645515.2020.1814098. Epub 2020 Sep 29.

Abstract

A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.

Keywords: SARS-CoV-2; neutralizing antibodies; receptor-binding domain; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology*
  • Antibodies, Viral / immunology*
  • COVID-19 / immunology*
  • Cell Line
  • HEK293 Cells
  • Humans
  • Mice
  • Pandemics / prevention & control
  • Protein Binding / immunology*
  • Protein Domains / immunology*
  • Recombinant Proteins / immunology
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Recombinant Proteins
  • Spike Glycoprotein, Coronavirus

Grants and funding

This study was supported by the Ministry of Science and Technology (MOST-109-3114-Y-001-001 and MOST-109-2327-B-002-009), National Taiwan University and Academia Sinica, Taiwan.